Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncolys BioPharmaTSE:4588 -2.06%40 Median PS Value is 円48.00 as of Jul. 14, 2026, which is 100% below its 10-year median of 18.54. GuruFocus rates TSE:4588 with a GF Score™ of 40/100 and a GF Value™ of 円363.33 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 278 Biotechnology companies, Oncolys BioPharma ranks worse than 99.64% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Oncolys BioPharma's Median PS Value or its related term are showing as below:
TSE:4588'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 8.25 Med: 18.54 Max: 53.65
Current: 52.54
During the past 13 years, the highest Price to Median PS Value of Oncolys BioPharma was 53.65. The lowest was 8.25. And the median was 18.54.
TSE:4588's Price-to-Median-PS-Value is ranked worse than 99.64% of 278
companies
in the Biotechnology industry
Industry Median: 0.63
vs TSE:4588: 52.54
Oncolys BioPharma (TSE:4588) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Oncolys BioPharma's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
2522.00
/
48.00
=
52.54
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncolys BioPharma Median PS Value Related Terms
Oncolys BioPharma Median PS Value Historical Data
* Premium members only.
The historical data trend for Oncolys BioPharma's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4588 vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Oncolys BioPharma's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncolys BioPharma Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncolys BioPharma's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Oncolys BioPharma's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 38.247.
Oncolys BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1.255.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncolys BioPharma (TSE:4588) has a Median PS Value of 円48.00 as of Jul. 14, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Oncolys BioPharma and its competitors. This is 159% above median its historical median of 18.54. Over the past decade, Oncolys BioPharma's Median PS Value has ranged from 8.25 to 53.65. According to the industry distribution chart, Oncolys BioPharma ranks #277 out of 278 companies in the Biotechnology industry, placing it in the top 99.6%.
Is Oncolys BioPharma's Median PS Value too high?
Oncolys BioPharma's current Median PS Value of 円48.00 is 159% above median its 10-year median of 18.54. Over the past 10 years, this metric has ranged from a low of 8.25 to a high of 53.65. Based on the distribution chart, Oncolys BioPharma ranks #277 out of 278 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncolys BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncolys BioPharma ranks #277 out of 278 companies for Median PS Value. This places Oncolys BioPharma in the lower half of its industry. The industry median Median PS Value is 0.63. Historically, Oncolys BioPharma's own Median PS Value has ranged from 8.25 to 53.65 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Oncolys BioPharma and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncolys BioPharma's current Median PS Value is 円48.00, which is 159% above median its own 10-year median of 18.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円363.33, compared to a current price of 円2,522.00 — trading 594.1% above its estimated fair value. The current Median PS Value is 円48.00, which is 159% above median its 10-year median of 18.54. Oncolys BioPharma's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current Median PS Value is 円48.00 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?
Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued.
The current stock price of 円2,522.00 is trading 594.1% above its estimated GF Value™ of 円363.33.
GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.
Key valuation signals for TSE:4588:
Median PS Value: 円48.00 (159% above median its 10-year median of 18.54)
GF Value™: 円363.33 vs. price of 円2,522.00 (594.1% above fair value)
No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
40GF Score
Get the complete analysis for TSE:4588
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4588 has been successfully added to your 
